The labeling of biosimilar products as “interchangeable” may be important in order to gain acceptance and use in the medical community. This article provides important information.
Sandoz mobilises critical medicine production in Europe europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.
Sandoz has launched a new antibiotic production plant in Austria along with a biosimilar development center in Germany. The units are in line with the firm’s aim to strengthen sustainable development and supply of critical medicines in Europe and other regions of the world.
On September 18, 2023, the FDA issued a new draft guidance “Labeling for Biosimilar and Interchangeable Biosimilar Products,” updating the previous labeling guidance “Labeling for.